Menu Search
Equities

Kenvue Inc

J4D:BER

Kenvue Inc

Actions
  • Price (EUR)21.97
  • Today's Change0.625 / 2.93%
  • Shares traded550.00
  • 1 Year change+22.74%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:48 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kenvue Inc. is a consumer health company. The Company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include Pain Care; Cough, Cold, and Allergy; and Other Self Care (Digestive Health; Smoking Cessation; Eye Care; and Other). The Skin Health and Beauty segment's product categories include face and body care and hair, sun, and others. The Essential Health segment's product categories include oral care, baby care and other essential health (women’s health, wound care, and other). Its differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec, and Nicorette. The Company has a global footprint through which it sells and distributes its product portfolio in more than 165 countries across its four regions. The four region consists of North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).

  • Revenue in USD (TTM)15.46bn
  • Net income in USD1.06bn
  • Incorporated2022
  • Employees21.78k
  • Location
    Kenvue Inc199 Grandview RoadSKILLMAN 08558United StatesUSA
  • Phone+1 (732) 524-0400
  • Fax+1 (302) 655-5049
  • Websitehttps://www.kenvue.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.